GLPwatch
Papers (10588)
Page 175 of 177, ranked by citation count.
- Comparison of low-dose liraglutide use versus other GLP-1 receptor agonists in patients without type 2 diabetes.
- Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation.
- [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?]
- Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes: a BRAVO model-based evaluation.
- Development of a Long-Acting and Stapled Dual Amylin and Calcitonin Receptor Agonist as Monotherapy and Combination with GLP-1R Agonists for the Treatment of Obesity.
- Semaglutide exposure in early pregnancy and pregnancy outcomes: A case report and review of literature.
- GLP-1 Agonists in Orthopedic Surgery: A Narrative Review of Bone Health and Surgical Implications.
- [Semaglutide-induced acute-on-chronic liver failure: A case report and literature review].
- [Onset of type 1 diabetes after treatment with online-prescribed semaglutide].
- Hormonal Contraception and Initiation of Semaglutide Therapy.
- Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.
- Semaglutide attenuates autistic-like behaviors in BTBR mice through the shaping of gut microbiota.
- In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, oral semaglutide did not increase CV events.
- Semaglutide restores metabolic and structural homeostasis along the gut-heart-metabolic axis in a cafeteria diet-induced obesity model.
- Two new doses of dulaglutide (Trulicity) for diabetes.
- Effects of Tirzepatide on Body Composition, Metabolic Parameters, and Sleep Outcomes: A Real-World One-Year Prospective Study.
- Dulaglutide in the era of tirzepatide and semaglutide: reaffirming its role in contemporary cardiometabolic care.
- Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.
- GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways.
- Retatrutide fact check: Has a man died after taking the unapproved weight loss jab?
- Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes.
- Semaglutide may reduce cardiovascular disease and heart failure.
- [Effects of semaglutide on mental health].
- Pre-Pregnancy GLP-1 Receptor Agonist or Tirzepatide Use and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry-Over Versus Post-Discontinuation Metabolic Rebound in a Multinational Federated Cohort.
- Indications, efficacy, and safety of glucagon-like peptide-1 receptor agonists in respiratory diseases: A systematic review.
- Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
- Risk factors for drug-related impaired gastric emptying: a pharmacovigilance analysis of the FDA adverse event reporting system.
- Do GLP-1 Receptor Agonists Sabotage Fat Grafts? : A Scoping Review of GLP-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer.
- [Effect of liraglutide on interleukin-1β expression in the pancreatic islets of OLETF rats].
- Urological Complications of Morbid Obesity and the Role of Bariatric Surgery and Glucagon-Like Peptide-1 Receptor Agonists in Their Management: A Systematic Review.
- Therapeutic potential of targeting ceramide for early cardiometabolic lipotoxicity in vivo study.
- A Systematic Review and Meta-Analysis Evaluating the Role of GLP-1 Receptor Agonists in Substance Use Disorders.
- Trends in Use of Obesity Medications and Metabolic and Bariatric Surgery Among All of Us Participants From 2003 to 2023.
- Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study.
- [Not Available].
- Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination - The REST trial study protocol.
- Dynamic structural analysis-based epitope prediction of Exendin-4 in aqueous solution.
- Semaglutide reduced a composite of CV events at 2 years in patients with type 2 diabetes and high CV risk.
- Holistic Management of Obesity in Patients with Incidental Cancer After Unprovoked Deep Vein Thrombosis: A Cardiometabolic and Antithrombotic Framework.
- In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 y.
- Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study.
- Semaglutide Inhibits Neuronal Apoptosis and Improves Cognitive Function in Mice after Traumatic Brain Injury, Mainly via the Caspase-Dependent Pathway.
- Understanding Obesity as a Multisystem Disease: Advancing Research, Redefining Diagnostic Criteria, and Establishing Modern Therapeutic Approaches.
- Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg.
- GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study.
- Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis.
- Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.
- Glucagonlike Peptide-1 (GLP-1) Receptor Agonists for Cardiometabolic Risk in Severe Mental Illness: A Narrative Review.
- Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes.
- [Pharmacological treatments for obesity : what does the future hold?]
- Semaglutid bessert HFpEF-Herzinsuffizienz.
- Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications.
- Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies.
- Tirzepatide ameliorates type 2 diabetes-associated male reproductive dysfunction via modulation of the Nrf2/Keap1 pathway.
- Multidimensional Predictors of Tirzepatide Efficacy: Clinical, Genetic, and Molecular Biomarkers for Glycemic, Weight, and Organ Protection.
- Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.
- Pre-Treatment Concerns and Their Association With Functioning and Well-Being During Incretin-Based Therapy: A Cross-Sectional Study.
- More on Semaglutide in Early Type 1 Diabetes. Reply.
- Efficacy of dulaglutide after switching from incretin-related drugs in patients with type 2 diabetes and inadequate glycemic control.
- Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.